Aligos Therapeutics Presents Positive Data at APASL 2025
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, ...
Aligos Therapeutics files to sell 6.25M shares of common stock for holders
EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holdersLight Up your Portfolio with Spark:Easily identify ...
A Path to a Healthier Future With Chronic Hepatitis B Virus Infection
Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...
Morningstar4d
Aligos Therapeutics Presents Positive Data at APASL 2025
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel ...
Mena FN3d
Aligos Therapeutics Presents Positive Data At APASL 2025
(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS,“Aligos”), a clinical ...
Nasdaq1d
Aligos Therapeutics, Inc. Common Stock (ALGS) Institutional Holdings
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...